In recent trading session, Novavax, Inc (NASDAQ:NVAX) saw 0.72 million shares changing hands at last check today with its beta currently measuring 2.50. Company’s recent per share price level of $6.94 trading at -$0.02 or -0.30% at last check today assigns it a market valuation of $1.12B. That most recent trading price of NVAX’s stock is at a discount of -156.63% from its 52-week high price of $17.81 and is indicating a premium of 27.81% from its 52-week low price of $5.01. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 4.39 million shares which gives us an average trading volume of 8.37 million if we extend that period to 3-months.
For Novavax, Inc (NVAX), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 2.71. Splitting up the data highlights that, out of 16 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 6 suggested the stock as a Hold whereas 10 see the stock as a Buy. 0 analyst(s) advised it as an Underweight.
Novavax, Inc (NASDAQ:NVAX) trade information
Upright in the red during last session for losing -0.30%, in the last five days NVAX remained trading in the red while hitting it’s week-highest on Tuesday, 07/15/25 when the stock touched $6.94 price level, adding 1.7% to its value on the day. Novavax, Inc’s shares saw a change of -54.11% in year-to-date performance and have moved -2.27% in past 5-day. Novavax, Inc (NASDAQ:NVAX) showed a performance of -1.30% in past 30-days. Number of shares sold short was 44.48 million shares which calculate 4.04 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 22 to the stock, which implies a rise of 68.45% to its recent value today. Analysts have been projecting 14 as a low price target for the stock while placing it at a high target of 174. It follows that stock’s current price would drop -101.73% in reaching the projected high whereas dropping to the targeted low would mean a loss of -101.73% for stock’s current value.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 25.88% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 298.25% while estimates for its earnings growth in next 5 years are of 44.15%.
Novavax, Inc (NASDAQ:NVAX)’s Major holders
Insiders are in possession of 8.78% of company’s total shares while institution are holding 57.19 percent of that, with stock having share float percentage of 62.70%. Investors also watch the number of corporate investors in a company very closely, which is 57.19% institutions for Novavax, Inc that are currently holding shares of the company. VANGUARD GROUP INC is the top institutional holder at NVAX for having 14.08 million shares of worth $178.19 million. And as of 2024-06-30, it was holding 9.4861 of the company’s outstanding shares.
The second largest institutional holder is BLACKROCK INC., which was holding about 11.85 million shares on 2024-06-30. The number of shares represents firm’s hold over 7.984 of outstanding shares, having a total worth of $149.98 million.
On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and iShares Trust-iShares Russell 2000 ETF are the top two Mutual Funds which own company’s shares. As of Mar 31, 2025 , the former fund manager was holding 4.79 shares of worth $33.09 million or 2.96% of the total outstanding shares. The later fund manager was in possession of 3.9 shares on May 31, 2025 , making its stake of worth around $26.99 million in the company or a holder of 2.41% of company’s stock.
